NYSEAM:CATXBiotechs
Why Perspective Therapeutics (CATX) Is Up 59.6% After New VMT-α-NET Trial Data And Expansion Plans
Perspective Therapeutics recently reported updated interim data from its ongoing Phase 1/2a trial of lead radiopharmaceutical candidate VMT-α-NET, indicating sustained anti-tumor activity, and issued a business update outlining clinical priorities and manufacturing expansion plans.
This combination of early clinical signals and investment in production capacity highlights how the company is positioning VMT-α-NET as a core asset in its radiopharmaceutical pipeline.
We’ll now examine how the...